Novolin L

   
Google
 
Web NewDrugInformation.com

Novolin L


Drug - Novolin L
The trade name of the product as shown on the labeling.

Dosage - INJECTABLE; INJECTION
The product dosage form and route separated by a semi-colon.

Active Ingredient(s) - Insulin Zinc Susp Recombinant Human
Multiple ingredients are in alphabetical order.

Strength - 100 UNITS/ML
The potency of the active ingredient(s), Insulin Zinc Susp Recombinant Human. May repeat for multiple part products.

Applicant - NOVO NORDISK INC
The firm name holding legal responsibility for Novolin L. The firm name is condensed to a maximum twenty character unique string.

New Drug Application (NDA) Number - 019965
The FDA assigned number to Novolin L. Format is nnnnnn.

Product Number - 001
The FDA assigned number to identify Novolin L. Each strength is a separate product. May repeat for multiple part products. Format is nnn.

Therapeutic Equivalence (TE) Code -
The TE Code indicates the therapeutic equivalence rating of generic to innovator Rx products.

Approval Date - Jun 25, 1991
The date Novolin L was approved as stated in the FDA approval letter to the applicant. The format is Mmm dd, yyyy. Products approved prior to the January 1, 1982 contain the phrase: "Approved prior to Jan 1, 1982".

Reference Listed Drug (RLD) - No
The pioneer or innovator of Novolin L. The RLD identifies the product Abbreviated New Drug Applications (ANDA) use as a reference. Format is Yes or No.

Type - OTC
The group or category of approved drugs Novolin L is in. Format is RX, OTC, DISCN.

Applicant Full Name - Novo Nordisk Inc
The full name of the firm holding legal responsibility for the new application of Novolin L.

Novolin L